Literature DB >> 21434686

Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase.

Sung Hee Hwang1, Karen M Wagner, Christophe Morisseau, Jun-Yan Liu, Hua Dong, Aaron T Wecksler, Bruce D Hammock.   

Abstract

A series of dual inhibitors containing a 1,5-diarylpyrazole and a urea were designed, synthesized, and evaluated as novel COX-2/sEH dual inhibitors in vitro using recombinant enzyme assays and in vivo using a lipopolysaccharide (LPS) induced model of pain in rats. The best inhibition potencies and selectivity for sEH and COX-2 over COX-1 were obtained with compounds (21b, 21i, and 21j) in which both the 1,5-diaryl-pyrazole group and the urea group are linked with a three-methylene group. Compound 21i showed the best pharmacokinetic profiles in both mice and rats (higher AUC and longer half-life). Following subcutaneous administration at 10 mg/kg, compound 21i exhibited antiallodynic activity that is more effective than the same dose of either a COX-2 inhibitor (celecoxib) or a sEH inhibitor (t-AUCB) alone, as well as coadministration of both inhibitors. Thus, these novel dual inhibitors exhibited enhanced in vivo antiallodynic activity in a nociceptive behavioral assay.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21434686      PMCID: PMC3281519          DOI: 10.1021/jm2001376

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  47 in total

1.  Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.

Authors:  Sabine Barbey; Laurence Goossens; Thierry Taverne; Joséphine Cornet; Valérie Choesmel; Céline Rouaud; Gilles Gimeno; Sylvie Yannic-Arnoult; Catherine Michaux; Caroline Charlier; Raymond Houssin; Jean Pierre Hénichart
Journal:  Bioorg Med Chem Lett       Date:  2002-03-11       Impact factor: 2.823

2.  The trouble with making combination drugs.

Authors:  Simon Frantz
Journal:  Nat Rev Drug Discov       Date:  2006-11       Impact factor: 84.694

3.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.

Authors:  R G Kurumbail; A M Stevens; J K Gierse; J J McDonald; R A Stegeman; J Y Pak; D Gildehaus; J M Miyashiro; T D Penning; K Seibert; P C Isakson; W C Stallings
Journal:  Nature       Date:  1996 Dec 19-26       Impact factor: 49.962

Review 4.  Cyclooxygenase inhibitors--current status and future prospects.

Authors:  G Dannhardt; W Kiefer
Journal:  Eur J Med Chem       Date:  2001-02       Impact factor: 6.514

5.  Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain.

Authors:  S A Kanaan; N E Saadé; J J Haddad; A M Abdelnoor; S F Atweh; S J Jabbur; B Safieh-Garabedian
Journal:  Pain       Date:  1996-08       Impact factor: 6.961

6.  The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

Authors:  P Prasit; Z Wang; C Brideau; C C Chan; S Charleson; W Cromlish; D Ethier; J F Evans; A W Ford-Hutchinson; J Y Gauthier; R Gordon; J Guay; M Gresser; S Kargman; B Kennedy; Y Leblanc; S Léger; J Mancini; G P O'Neill; M Ouellet; M D Percival; H Perrier; D Riendeau; I Rodger; R Zamboni
Journal:  Bioorg Med Chem Lett       Date:  1999-07-05       Impact factor: 2.823

7.  Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.

Authors:  T Kirchner; D C Argentieri; A G Barbone; M Singer; M Steber; J Ansell; S A Beers; M P Wachter; W Wu; E Malloy; A Stewart; D M Ritchie
Journal:  J Pharmacol Exp Ther       Date:  1997-08       Impact factor: 4.030

Review 8.  Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis.

Authors:  C A C Hyde; S Missailidis
Journal:  Int Immunopharmacol       Date:  2009-02-23       Impact factor: 4.932

Review 9.  Cyclooxygenases: structural and functional insights.

Authors:  Carol A Rouzer; Lawrence J Marnett
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

10.  Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1.

Authors:  Andreas Koeberle; Ulf Siemoneit; Ulrike Bühring; Hinnak Northoff; Stefan Laufer; Wolfgang Albrecht; Oliver Werz
Journal:  J Pharmacol Exp Ther       Date:  2008-06-11       Impact factor: 4.030

View more
  48 in total

Review 1.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

Authors:  Hong C Shen; Bruce D Hammock
Journal:  J Med Chem       Date:  2012-01-17       Impact factor: 7.446

2.  A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat.

Authors:  Md Abdul Hye Khan; Sung Hee Hwang; Amit Sharma; John A Corbett; Bruce D Hammock; John D Imig
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-07-16       Impact factor: 3.072

3.  Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.

Authors:  Guodong Zhang; Dipak Panigrahy; Sung Hee Hwang; Jun Yang; Lisa M Mahakian; Hiromi I Wettersten; Jun-Yan Liu; Yanru Wang; Elizabeth S Ingham; Sarah Tam; Mark W Kieran; Robert H Weiss; Katherine W Ferrara; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

Review 4.  Role of epoxy-fatty acids and epoxide hydrolases in the pathology of neuro-inflammation.

Authors:  Sean D Kodani; Christophe Morisseau
Journal:  Biochimie       Date:  2019-02-01       Impact factor: 4.079

5.  Celecoxib Does Not Protect against Fibrosis and Inflammation in a Carbon Tetrachloride-Induced Model of Liver Injury.

Authors:  Todd R Harris; Sean Kodani; Amy A Rand; Jun Yang; Denise M Imai; Sung Hee Hwang; Bruce D Hammock
Journal:  Mol Pharmacol       Date:  2018-05-29       Impact factor: 4.436

Review 6.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.

Authors:  Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2018-11-14       Impact factor: 11.685

7.  Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.

Authors:  Sean D Kodani; Saavan Bhakta; Sung Hee Hwang; Svetlana Pakhomova; Marcia E Newcomer; Christophe Morisseau; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2018-01-04       Impact factor: 2.823

Review 8.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

Review 9.  The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain.

Authors:  Sean D Kodani; Bruce D Hammock
Journal:  Drug Metab Dispos       Date:  2015-03-11       Impact factor: 3.922

Review 10.  Novel therapies for hemodialysis vascular access dysfunction: myth or reality?

Authors:  Christi M Terry; Laura M Dember
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.